Puma Biotechnology
PBYI
139 hedge funds and large institutions have $442M invested in Puma Biotechnology in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 31 reducing their positions, and 40 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 31
76% more call options, than puts
Call options by funds: $5.05M | Put options by funds: $2.88M
1.31% more ownership
Funds ownership: 88.74% → 90.05% (+1.3%)
12% less funds holding
Funds holding: 158 → 139 (-19)
43% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 40
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
67% less capital invested
Capital invested by funds: $1.32B → $442M (-$882M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$68.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.5M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$14M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$13.4M |
| 5 |
Morgan Stanley
New York
|
+$8.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$84.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$34.9M |
| 3 |
O
OrbiMed
New York
|
-$28.9M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18.1M |
| 5 |
First Manhattan
New York
|
-$16.5M |
PBYI Hedge Fund Activity: Q2 2019 in Review
139 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2019, worth a combined $442M — down 67% from $1.32B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of PBYI and 23 opened new positions — a net loss of 17 holders — while 31 trimmed existing stakes and 60 added.
The largest buyer was State Street, adding an estimated $68.9M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $84.2M sold.
- 139 institutional investors held Puma Biotechnology (PBYI) as of Q2 2019, down from 158 in Q1 2019.
- Funds reported $442M of Puma Biotechnology stock for Q2 2019, down 67% quarter-over-quarter.
- 23 funds opened new Puma Biotechnology positions in Q2 2019 and 40 closed out, a net change of -17 holders.
- The largest Puma Biotechnology buyer in Q2 2019 was State Street, an estimated $68.9M added.
- The largest Puma Biotechnology seller in Q2 2019 was Janus Henderson Group, an estimated $84.2M sold.
Based on aggregated 13F filings for Q2 2019.